The human papillomavirus type 16 E5 oncoprotein synergizes with EGF-receptor signaling to enhance cell cycle progression and the down-regulation of p27Kip1

Virology

Volumn 400, Issue 1, 2010, Pages 44-52

  Pedroza Saavedra, Adolfo ^a   Lam, Eric W F ^b   Esquivel Guadarrama, Fernando ^c   Gutierrez Xicotencatl, Lourdes ^a  

^a INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSIDAD AUTÓNOMA DEL ESTADO DE MORELOS   (Mexico)

Author keywords

Cell cycle regulation; E5 oncoprotein; EGF receptor; High risk papillomaviruses; HPV 16; p27Kip1

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; E5 ONCOPROTEIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ONCOPROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ARTICLE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL DENSITY; CELL GROWTH; CELL STIMULATION; CELL STRAIN 3T3; CELL TRANSFORMATION; CONTROLLED STUDY; DNA SYNTHESIS; DOWN REGULATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; GROWTH RATE; HALF LIFE TIME; HUMAN PAPILLOMAVIRUS TYPE 16; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; VIRUS ONCOGENE; WILD TYPE;

ANIMALS; BASE SEQUENCE; CELL CYCLE; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DNA PRIMERS; DOWN-REGULATION; GENES, VIRAL; HOST-PATHOGEN INTERACTIONS; HUMAN PAPILLOMAVIRUS 16; HUMANS; MICE; NIH 3T3 CELLS; ONCOGENE PROTEINS, VIRAL; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION;

HUMAN PAPILLOMAVIRUS TYPE 16; PAPILLOMAVIRIDAE;

EID: 77649182253     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2010.01.009     Document Type: Article

References (99)

1. Abbas T., and Dutta A. p21 in cancer: intricate networks and multiple activities. Nat. Rev. Cancer 9 (2009) 400-414
2. Abukhdeir A.M., and Park B.H. p21 and p27: roles in carcinogenesis and drug resistance. Expert Rev. Mol. Med. 10 (2008) e19
3. +-ATPase is not sufficient for biological activity, using mammalian and yeast expression systems. Virology 272 (2000) 315-325
4. Akerman G.S., Tolleson W.H., Brown K.L., Zyzak L.L., Mourateva E., Engin T.S., Basaraba A., Coker A.L., Creek K.E., and Pirisi L. Human papillomavirus type 16 E6 and E7 cooperate to increase epidermal growth factor receptor (EGFR) mRNA levels, overcoming mechanisms by which excessive EGFR signaling shortens the life span of normal human keratinocytes. Cancer Res. 61 (2001) 3837-3843
5. +-ATPase. J. Gen. Virol. 82 (2001) 2353-2362
6. Bahnassy A.A., Zekri A.R., Saleh M., Lotayef M., Moneir M., and Shawki O. The possible role of cell cycle regulators in multistep process of HPV-associated cervical carcinoma. BMC Clin. Pathol. 7 (2007) 4-15
7. Belle A., Tanay A., Bitincka L., Shamir R., and O'Shea EK. Quantification of protein half-lives in the budding yeast proteome. Proc. Natl. Acad. Sci. U.S.A. 103 35 (2006) 13004-13009
8. Berezutskaya E., Yu B., Morozov A., Raychaudhuri P., and Bagchi S. Differential regulation of the pocket domains of the retinoblastoma family proteins by the HPV16 E7 oncoprotein. Cell Growth Differ. 8 (1997) 1277-1286
9. Besson A., Dowdy S.F., and Roberts J.M. CDK inhibitors: cell cycle regulators and beyond. Dev. Cell 14 (2008) 159-169
10. Bloom J., and Pagano M. Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin. Cancer Biol. 13 (2003) 41-47
11. Borriello A., Cucciolla V., Oliva A., Zappia V., and Della Ragione F. p27Kip1 metabolism: a fascinating labyrinth. Cell Cycle 6 (2007) 1053-1061
12. Bouvard V., Matlashewski G., Gu Z.-M., Storey A., and Banks L. The human papillomavirus type 16 E5 gene cooperates with the E7 gene to stimulate proliferation of primary cells and increases viral gene expression. Virology 203 (1994) 73-80
13. Briggs M.W., Adam J.L., and McCance D.J. The human papillomavirus type 16 E5 protein alters vacuolar H(+)-ATPase function and stability in Saccharomyces cerevisiae. Virology 280 (2001) 169-175
14. Cánepa E.T., Scassa M.E., Ceruti J.M., Marazita M.C., Carcagno A.L., Sirkin P.F., and Ogara M.F. INK4 proteins, a family of mammalian CDK inhibitors with novel biological functions. IUBMB Life 59 (2007) 419-426
15. Carraway III K.L., and Cantley L.C. A neu acquaintance for erbB3 and erbB4: a role for receptor hetero-dimerization in growth signaling. Cell 78 (1994) 5-8
16. Catzavelos C., Bhattacharya N., Ung Y.C., Wilson J.A., Roncari L., Sandhu C., Shaw P., Yeger H., Morava-Protzner I., Kapusta L., Franssen E., Pritchard K.I., and Slingerland J.M. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat. Med. 3 (1997) 227-230
17. ink4. Mol. Cell. Biol. 15 (1995) 2682-2688
18. Chen S.L., and Mounts P. Transforming activity of E5a protein of human papillomavirus type 6 in NIH 3T3 and C127 cells. J. Virol. 64 (1990) 3226-3233
19. Chen S.L., Tsao L.T., and Tsao Y.P. Antisense oligodeoxynucleotides to c-jun inhibits proliferation of transformed NIH 3T3 cells induced by E5a of HPV11. Cancer Lett. 85 (1994) 119-123
20. Chen S.L., Tsao Y.P., Yang C.M., Lin Y.K., Huang C.H., and Kuo S.W. Differential induction and regulation of the c-jun, junB, junD and c-fos by human papillomavirus type 11 E5a oncoprotein. J. Gen. Virol. 76 (1995) 2653-2659
21. Chen S.L., Huang C.H., Tsai T.C., Lu K.Y., and Tsao Y.P. The regulation mechanism of c-jun and junB by human papillomavirus type 16 E5 oncoprotein. Arch. Virol. 141 (1996) 791-800
22. Chen S.L., Lin Y.K., Li L.Y., Tsao Y.P., Lo H.Y., Wang W.B., and Tsai T.C. E5 proteins of human papillomavirus types 11 and 16 transactivate the c-fos promoter through the NF1 binding element. J. Virol. 70 (1996) 8558-8563
23. Chen S.L., Lin S.T., Tsai T.C., Hsiao W.C., and Tsao Y.P. ErbB4 (JM-b/CYT-1)-induced expression and phosphorylation of c-Jun is abrogated by human papillomavirus type 16 E5 protein. Oncogene 26 (2007) 42-53
24. Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). Proc. Natl. Acad. Sci. U.S.A. 95 3 (1998) 1091-1096
25. Cheng M., Olivier P., Diehl J.A., Fero M., Roussel M.F., Roberts J.M., and Sherr CJ. The p21 (Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J. 18 6 (1999) 1571-1583
26. Conrad M., Bubb V.J., and Schlegel R. The human papillomavirus type 6 and 16 E5 proteins are membrane-associated proteins which associate with the 16-kilodalton pore-forming protein. J. Virol. 67 (1993) 6170-6178
27. Crusius K., Auvinen E., and Alonso A. Enhancement of EGF- and PMA-mediated MAP kinase activation in cells expressing the human papillomavirus type 16 E5 protein. Oncogene 15 (1997) 1437-1444
28. Crusius K., Auvinen E., Steuer B., Gaissert H., and Alonso A. The human papillomavirus type 16 E5-protein modulates ligand-dependent activation of the EGF receptor family in the human epithelial cell line HaCat. Exp. Cell Res. 241 (1998) 76-83
29. Di Domenico F., Foppoli C., Blarzino C., Perluigi M., Paolini F., Morici S., Coccia R., Cini C., and De Marco F. Expression of Human papillomavirus type 16 E5 protein in amelanotic melanoma cells regulates endo-cellular pH and restores tyrosinase activity. J. Exp. Clin. Cancer Res. 28 (2009) 4
30. Dyson N., Guida P., Münger K., and Harlow E. Homologous sequences in adenovirus E1A and human papillomavirus E7 proteins mediate interaction with the same set of cellular proteins. J. Virol. 66 (1992) 6893-6902
31. Durand B., Fero M.L., Roberts J.M., and Raff M.C. p27Kip1 alters the response of cells to mitogen and is part of a cell-intrinsic timer that arrests the cell cycle and initiates differentiation. Curr. Biol. 8 (1998) 431-440
32. El-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., and Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 75 (1993) 817-825
33. Fehrmann F., Klumpp D.J., and Laimins L.A. Human papillomavirus type 31 E5 protein supports cell cycle progression and activates late viral functions upon epithelial differentiation. J. Virol. 77 (2003) 2819-2831
34. Genther Williams S.M., Disbrow G.L., Schlegel R., Lee D., Threadgill D.W., and Lambert P.F. Requirement of epidermal growth factor receptor for hyperplasia induced by E5, a high-risk human papillomavirus oncogene. Cancer Res. 65 (2005) 6534-6542
35. Gryfe R., Swallow C., Bapat B., Redston M., Gallinger S., and Couture J. Molecular biology of colorectal cancer. Curr. Prob. Cancer 21 (1997) 233-300
36. Gu Y., Turck C.W., and Morgan D.O. Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature 366 (1993) 707-710
37. Gu Z., and Matlashewski G. Effect of human papillomavirus type 16 oncogenes on MAP kinase activity. J. Virol. 69 (1995) 8051-8056
38. INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev. 8 (1994) 2939-2952
39. INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 371 (1994) 257-261
40. Harper J.W., Adami G.R., Wei N., Keyomarsi K., and Elledge S.J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75 (1993) 805-816
41. Kip1 accumulation during the cell cycle. Science 271 (1996) 1861-1864
42. Hirai H., Roussel M.F., Kato J.Y., Ashmun R.A., and Sherr C.J. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol. Cell. Biol. 15 (1995) 2672-2681
43. Hitomi M., Yang K., Guo Y., Fretthold J., Harwalkar J., and Stacey D.W. p27Kip1 and cyclin dependent kinase 2 regulate passage through the restriction point. Cell Cycle 5 (2006) 2281-2289
44. Hubbert N.L., Sedman S.A., and Schiller J.T. Human papillomavirus type 16 E6 increases the degradation rate of p53 in human keratinocytes. J. Virol. 66 (1992) 6237-6241
45. Huibregtse J.M., Scheffner M., and Howley P.M. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J. 10 (1991) 4129-4135
46. Johnston D., Hall H., DiLorenzo T.P., and Steinberg B.M. Elevation of the epidermal growth factor receptor and dependent signaling in human papillomavirus-infected laryngeal papillomas. Cancer Res. 59 (1999) 968-974
47. Kip1) of cyclin-dependent kinase 4 activation. Cell 79 (1994) 487-496
48. Kato A., Takahashi H., Takahashi Y., and Matsushime H. Inactivation of the cyclin D-dependent kinase in the rat fibroblast cell line, 3Y1, induced by contact inhibition. J. Biol. Chem. 272 (1997) 8065-8070
49. Kim S.H., Juhnn Y.S., Kang S., Park S.W., Sung M.W., Bang Y.J., and Song Y.S. Human papillomavirus 16 E5 up-regulates the expression of vascular endothelial growth factor through the activation of epidermal growth factor receptor, MEK/ERK1, 2 and PI3K/Akt. Cell. Mol. Life Sci. 63 (2006) 930-938
50. Kivi N., Greco D., Auvinen P., and Auvinen E. Genes involved in cell adhesion, cell motility and mitogenic signaling are altered due to HPV 16 E5 protein expression. Oncogene 27 (2008) 2532-2541
51. Kip2 a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev. 9 (1995) 639-649
52. Leechanachai P., Banks L., Moreau F., and Matlashewski G. The E5 gene from human papillomavirus type 16 is an oncogene which enhances growth factor-mediated signal transduction to the nucleus. Oncogene 7 (1992) 19-25
53. Leptak C., Ramon y Cajal S., Kulke R., Horwitz B.H., Riese D.J., Dotto G.P., and diMaio D. Tumorigenic transformation of murine keratinocytes by the E5 gene of bovine papillomavirus type 1 and human papillomavirus type 16. J. Virol. 65 (1991) 7078-7083
54. Lewis C., Baro M.F., Marques M., Grüner M., Alonso A., and Bravo I.G. The first hydrophobic region of the HPV16 E5 protein determines protein cellular location and facilitates anchorage-independent growth. Virol. J. 5 (2008) 30-39
55. Li S., Couvillon A.D., Brasher B.B., and Van Etten R.A. Tyrosine phosphorylation of Grb2 by Bcr/Abl and epidermal growth factor receptor: a novel regulatory mechanism for tyrosine kinase signaling. EMBO J. 20 (2001) 6793-6804
56. Martin P., Vass W.C., Schiller J.T., Lowy D.R., and Velu T.J. The bovine papillomavirus E5 transforming protein can stimulate the transforming activity of EGF and CSF-1 receptors. Cell 59 (1989) 21-32
57. Cip1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev. 9 (1995) 650-662
58. Maufort J.P., Genther Williams S.M., Pitot H.C., and Lambert P.F. Human papillomavirus 16 E5 oncogene contributes to two stages of skin carcinogenesis. Cancer Res. 67 (2007) 6106-6112
59. Moeller S.J., Head E.D., and Sheaff R.J. p27Kip1 inhibition of GRB2-SOS formation can regulate Ras activation. Mol. Cell. Biol. 23 (2003) 3735-3752
60. Morgan D.O. Principles of CDK regulation. Nature 374 (1995) 131-134
61. Mori M., Mimori K., Shiraishi T., Tanaka S., Ueo H., Sugimachi K., and Akiyoshi T. p27 expression and gastric carcinoma. Nat. Med. 3 (1997) 593
62. Muñoz N., Bosch F.X., de Sanjosé S., and Shah K.V. The role of HPV in the etiology of cervical cancer. Mutat. Res. 305 (1994) 293-301
63. Muraoka R.S., Lenferink A., Law B., Hamilton E., Brantley D.M., Roebuck L.R., and Arteaga CL. Erb2/Neu-induced cyclin D1-dependent transformation is accelerated in p27-haploinsufficient mammary epithelial cells but impaired in p27-null cells. Mol. Cell. Biol. 22 7 (2002) 2204-2219
64. Nath R., Mant C.A., Kell B., Cason J., and Bible J.M. Analyses of variant human papillomavirus type-16 E5 proteins for their ability to induce mitogenesis of murine fibroblasts. Cancer Cell Int. 6 (2006) 19-27
65. Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 372 (1994) 570-573
66. O'Brien V., Grindlay G.J., and Campo M.S. Cell transformation by the E5/E8 protein of bovine papillomavirus type 4. p27(Kip1), elevated through increased protein synthesis, is sequestered by cyclin D1-CDK4 complexes. J. Biol. Chem. 276 (2001) 33861-33868
67. Oetke C., Auvinen E., Pawlita M., and Alonso A. Human papillomavirus type 16 E5 protein localizes to the Golgi apparatus but does not grossly affect cellular glycosylation. Arch. Virol. 145 (2000) 2183-2191
68. Ogiso Y., Gutierrez L., Wrathall L.S., Lu Y.Y., Blair D.G., Clanton D.J., Hwang Y.W., and Shih T.Y. Transdominant suppressor mutations of the H-ras oncogene. Cell Growth Differ. 1 (1990) 217-224
69. Pim D., Collins M., and Banks L. Human papillomavirus type 16 E5 gene stimulates the transforming activity of the epidermal growth factor receptor. Oncogene 7 (1992) 27-32
70. Kip1, a cyclin-cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev. 8 (1994) 9-22
71. Polyak K., Lee M.H., Erdjument-Bromage H., Koff A., Roberts J.M., Tempst P., and Massague J. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78 (1994) 59-66
72. Reynisdottir I., Polyak K., Iavarone A., and Massague J. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-β. Genes Dev. 9 (1995) 1831-1845
73. +-ATPase can be dissociated from the E5-mediated epidermal growth factor receptor overactivation. Oncogene 19 (2000) 3727-3732
74. Scheffner M., Huibregtse J.M., Vierstra R.D., and Howley P.M. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75 (1993) 495-505
75. Schwartz R.H. T cell clonal anergy. Curr. Opin. Immunol. 9 (1997) 351-357
76. Seedorf K., Krammer G., Dürst M., Suhai S., and Röwekamp W.G. Human papillomavirus type 16 DNA sequence. Virology 145 (1985) 181-185
77. Serrano M., Hannon G.J., and Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366 (1993) 704-707
78. Sherr C.J., and Roberts J.M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 9 (1995) 1149-1163
79. Sherr C.J., and Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13 (1999) 1501-1512
80. Straight S.M., Hinkle P.M., Jewers R.J., and McCance D.J. The E5 oncoprotein of human papillomavirus type 16 transforms fibroblasts and affects the down-regulation of the epidermal growth factor receptor in keratinocytes. J. Virol. 67 (1993) 4521-4532
81. Straight S.W., Herman B., and McCance D.J. The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes. J. Virol. 69 (1995) 3185-3192
82. Suprynowicz F.A., Disbrow G.L., Krawczyk E., Simic V., Lantzky K., and Schlegel R. HPV-16 E5 oncoprotein upregulates lipid raft components caveolin-1 and ganglioside GM1 at the plasma membrane of cervical cells. Oncogene 27 (2008) 1071-1078
83. Swanson C., Ross J., and Jackson P.K. Nuclear accumulation of cyclin E/Cdk2 triggers a concentration-dependent switch for the destruction of p27Xic1. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 7796-7801
84. Takami K., Yana I., Kurahashi H., and Nishisho I. Multistep carcinogenesis in colorectal cancers. Southeast Asian J. Trop. Med. Public Health 26 (1995) 190-196
85. Kip1 down-regulation, passage through the restriction point, and entry into S phase in growth factor stimulated NIH3T3 fibroblasts. Mol. Cell. Biol. 17 (1997) 5348-5358
86. Tomakidi P., Cheng H., Kohl A., Komposch G., and Alonso A. Modulation of the epidermal growth factor receptor by the human papillomavirus type 16 E5 protein in raft cultures of human keratinocytes. Eur. J. Cell. Biol. 79 (2000) 407-412
87. Towbin H., Staehelin T., and Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. U.S.A. 76 (1979) 4350-4354
88. WafI/SdiI/CipI gene expression in fibroblasts and keratinocytes. J. Virol. 70 (1996) 7535-7539
89. Tungteakkhun S.S., and Duerksen-Hughes P.J. Cellular binding partners of the human papillomavirus E6 protein. Arch. Virol. 153 (2008) 397-408
90. Ungermannova D., Gao Y., and Liu X. Ubiquitination of p27Kip1 requires physical interaction with cyclin E and probable phosphate recognition by SKP2. J. Biol. Chem. 280 (2005) 30301-30309
91. Velu T.J., Beguinot L., Vass W.C., Zhang K., Pastan I., and Lowy D.R. Retroviruses expressing different levels of the normal epidermal growth factor receptor. J. Cell. Biochem. 39 (1989) 153-166
92. Vervoorts J., and Lüscher B. Post-translational regulation of the tumor suppressor p27(KIP1). Cell. Mol. Life Sci. 65 (2008) 3255-3264
93. Werness B.A., Levine A.J., and Howley P.M. Association of the human papillomavirus types 16 and 18 E6 proteins with p53. Science 248 (1990) 76-79
94. Wise-Draper T.M., and Wells S.I. Papillomavirus E6 and E7 proteins and their cellular targets. Front. Biosci. 13 (2008) 1003-1017
95. Yanagisawa K., Kosaka A., Iwahana H., Nakanishi M., and Tominaga S.I. Opposite regulation of the expression of cyclin-dependent kinase inhibitors during contact inhibition. J. Biochem. 125 (1999) 36-40
96. Zhang B., Spandau D.F., and Roman A. E5 protein of human papillomavirus type 16 protects human foreskin keratinocytes from UV B-irradiation-induced apoptosis. J. Virol. 76 (2002) 220-231
97. Zhang K., Sun J., Liu N., Wen D., Chang D., Thomason A., and Yoshinaga S.K. Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2. J. Biol. Chem. 271 (1996) 3884-3890
98. Zhu X.F., Liu Z.C., Xie B.F., Li Z.M., Feng G.K., Yang D., and Zeng Y.X. EGFR tyrosine kinase inhibitor AG1478 inhibits cell proliferation and arrests cell cycle in nasopharyngeal carcinoma cells. Cancer Lett. 169 (2001) 27-32
99. zur Hausen H. Papillomavirus infections-a major cause of human cancers. Biochim. Biophys. Acta 1288 (1996) F55-F78